Trial · NCT03334318
PERL Continuous Glucose Monitoring (CGM) Study
NCT03334318, Completed, Joslin Diabetes Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. PERL Continuous Glucose Monitoring (CGM) Study. Trials, record NCT03334318. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03334318
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PERL Continuous Glucose Monitoring (CGM) Study
- NCT number
- NCT03334318
- Status
- Completed
- Enrollment
- 175 participants, actual
- Lead sponsor
- Joslin Diabetes Center
- Conditions
- Diabetic Nephropathies
- Interventions
Mean blood glucose, Blood glucose CV, % time 70-180 mg/dL, % time below 54 mg/dL, % time above 180 mg/dL, % time above 250 mg/dL, MAGE (Mean amplitude of glucose excursions), LBGI (Low Blood Glucose Index), HBGI (High Blood Glucose Index), Allopurinol, Placebo
- First posted
- 2017-11-07
- Last updated
- 2022-03-29
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | iGFR at the end of the PERL trial | Week 164 of the PERL trial | Glomerular filtration rate (GFR) at the end of the PERL trial, measured by the plasma clearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline. |
| Secondary | HbA1c at week 80 of the PERL trial | Week 80 of the PERL Trial | Hba1c value at week 80 of the PERL trial |
| Secondary | HbA1c at week 96 of the PERL trial | Week 96 of the PERL Trial | Hba1c value at week 96 of the PERL trial |
| Secondary | HbA1c at week 112 of the PERL trial | Week 112 of the PERL Trial | Hba1c value at week 112 of the PERL trial |
| Secondary | HbA1c at week 128 of the PERL trial | Week 128 of the PERL Trial | Hba1c value at week 128 of the PERL trial |
| Secondary | HbA1c at week 142 of the PERL trial | Week 142 of the PERL Trial | Hba1c value at week 142 of the PERL trial |
| Secondary | HbA1c at week 156 of the PERL trial | Week 156 of the PERL Trial | Hba1c value at week 156 of the PERL trial |
| Secondary | HbA1c at week 164 of the PERL trial | Week 164 of the PERL Trial | Hba1c value at week 164 of the PERL trial |
| Secondary | Mean blood glucose | From week 80 to week 164 of the PERL trial | Mean of blood glucose values measured by continuous glucose monitoring |
| Secondary | CV (coefficient of variation) of blood glucose | From week 80 to week 164 of the PERL trial | Coefficient of variation of blood glucose values measured by continuous glucose monitoring |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03334318
GET https://conductscience.org/api/trials/v1/NCT03334318/registered